

solution is selected from the group consisting of lactated Ringer's solution, PlasmaLyte-A™, Normosol-R™, Veen-D™, Polysal®, and Hank's balanced salt solution.

Please add the following claims:

49. (New) The method of claim 26 wherein the medium comprises arabinogalactan.
50. (New) The method of claim 26 further comprising a cryoprotective agent that penetrates the cell membrane.
51. (New) The method of claim 50 wherein the cryoprotective agent that penetrates the cell membrane is glycerol or propylene glycol.
52. (New) The method of claim 26 wherein the lymphocytes which are modified *ex vivo* are activated lymphocytes or genetically modified lymphocytes.

Remarks

Reconsideration and withdrawal of the rejections, in view of the amendments and remarks herein, is respectfully requested. Claims 9-10, 23, 29, and 45-46 are canceled, claims 1, 14, 26, 31, and 37 are amended, and claims 49-52 are added. Claims 1-8, 11-12, 14, 16-17, 19-22, 24, 26-28, 30-44, and 47-52 are now pending.

Support for amended claims 1, 14, 26, and 31 is found in originally-filed claims 9-10 and 13, and at page 4, line 4 of the specification.

Support for amended claim 37 is found in originally-filed claims 9-10 and 13, and at page 4, line 4, page 6, lines 17-25, and page 14, line 26-page 16, line 13 of the specification

New claims 49-52 are supported by originally-filed claims 3-5 and 13.

The Examiner is thanked for the courtesies extended to Applicant's Representative and Dr. Hubel in the telephonic interview conducted on April 22, 2002. In the interview, Dr. Hubel clarified that the invention includes biocompatible, arabinogalactan (AG) containing cryopreservation media suitable for infusion, and that cryopreservation media which contains tissue culture media, dimethylsulfoxide (DMSO) or serum are not suitable for infusion, e.g.,

multiple infusions in humans. Dr. Hubel also indicated that a composition containing 50% w/v AG is not suitable for infusion due to its viscosity.

Dr. Hubel explained that, in contrast to the cell lines described in WO 97/35472, the cells that are cryopreserved in the biocompatible media of the invention are primary hematopoietic cells which, with the exception of stem cells, do not have a high proliferative capacity. Dr. Hubel also explained that primary hematopoietic cells have physical and biological properties that are different than other cells. Those properties, along with the composition of the cryopreservation solution and cooling rate, influence the ability of cells to survive the stresses of freezing and thawing. Thus, Dr. Hubel concluded that the disclosure in WO 97/35472, which generally describes the use of AG in cryopreservation media for immortalized mammalian somatic cells but fails to teach or suggest an AG-containing composition and a cooling rate for primary hematopoietic cells, provides no teaching or suggestion of AG-containing compositions or methods for cryopreserving primary hematopoietic cells.

The Examiner rejected claims 1-12, 14, 1-17, 19-24, and 26-48 under 35 U.S.C. § 102(a) as anticipated by, or in the alternative under 35 U.S.C. § 103(a) as obvious over, WO 97/35472. These rejections, as they may be maintained with respect to the pending claims, are respectfully traversed.

WO 97/35472 relates to the use of AG in cryopreservation media for immortalized mammalian somatic cells. Although WO 97/35472 indicates that the described media may be employed with a variety of cell types including human cells (page 5, line 2) and blood cells (page 10, line 4), the only data provided in the WO 97/35478 specification is for seven lines of immortalized mammalian cells (page 13). These included three lines derived from rodent epithelial cells, a line derived from mink fibroblasts, a line derived from human fibroblasts, a line derived from bovine endothelial cells (CPAE cells), and a line derived from murine pre-neoplastic mammary cells. Thus, no blood-derived hematopoietic cells are represented in the seven lines of cells disclosed in WO 97/35472.

These seven lines were frozen in 6 different media (Table 1). For media containing AG, it is disclosed that AG was prepared as a 50% w/v concentrated stock dissolved in a buffered isotonic salt solution. This stock was used directly (medium 3, i.e., 50% AG) or in combination with other components. Medium 4 has 20% AG and 10% DMSO; medium 6 has 15% AG and

20% serum, medium 2 has 10% AG and 20% DMSO; and medium 5 has 10% AG, 10% DMSO and 20% serum. Medium 1 has 10% DMSO and 20% serum (no AG). Note that media which includes DMSO or serum is not generally suitable for administration to a human due to DMSO-related toxicity or the potential for a transmissible infectious agent in serum.

With respect to immediate post-thaw viability for all cell types tested, it is disclosed that there was no difference in post-thaw viability for 4 of the media relative to “the industry standard” (cell culture medium + serum + DMSO) (page 14), however, cells frozen in media with AG and serum had reduced viability. It is also noted that there was “substantially no difference” in plating efficiency at day 1 for 6/7 of the cell types (page 14). At six days post-thaw, it is disclosed that there was “substantially no difference” between treatment groups (page 15). Table 2 shows the ranking of the media with respect to growth rates (Day 6/Day 1) for CPAE cells (media 3 > media 5 > media 2 > media 1 > media 4 > media 6). WO 97/35472 concludes that AG “can be used to replace serum in a standard freezing medium, in a formulation with DMSO, for all cell types studied” (page 15, emphasis added) and that freezing in 50% w/v AG was better or equivalent to the standard media for 5/7 cell types tested (page 15).

WO 97/35472 generally discloses that the cells may be cooled or frozen during storage to about or below 4°C, for example to about -200°C. An exemplary freezing procedure is described as resuspending cells in an AG-containing freezing medium (1×10^6 - 1×10^7 cells/vial), aliquoted into 1.8 ml cryovials, equilibrated for about 30 minutes at 4°C, step-cooled for 18 hours at -80°C and immediately transferred to liquid nitrogen (-196°C) (page 8 and Example 2).

Nevertheless, methods and compositions useful to cryopreserve one cell type are not necessarily the same as the methods and compositions employed for other cell types, as each cell type has different biological and physical properties. In this regard, the Examiner is requested to reconsider the Rule 132 Declaration filed with the Amendment on August 27, 2001, executed by Dr. Allison Hubel, the inventor of subject matter claimed in the above-identified application. In the Declaration, Dr. Hubel states that a variety of interrelated factors influence the ability of cells to survive the stresses of freezing and thawing including (1) the composition of the cryopreservation solution; (2) the temperature history of the sample during cooling (e.g., cooling rate); and (3) the biological and biophysical characteristics of the cell/tissue being frozen

(paragraph 5 of the Declaration). Dr. Hubel also states that during rapid cooling, there is insufficient time for water to leave the cell in response to the increase in extracellular solution concentration resulting from the removal of water experienced during freezing (paragraph 7 of the Declaration). Undercooling of the cell relative to the extracellular solution results in intracellular ice formation, a lethal event, and slow cooling can result in excessive dehydration of the cell that is also damaging to the cell (paragraph 7 of the Declaration). Dr. Hubel also states that the relative water content of a cell during freezing is a function of the cell type (with each cell type exhibiting its own unique biophysical characteristics) and the function of the solution composition in which the cell is suspended (paragraph 7 of the Declaration). Evidence that survival and cooling rate vary with the composition, and that different cell types have different cooling rates when present in the same freezing medium, is provided in paragraphs 8 and 9 of the Declaration.

In this regard, the Examiner is also requested to reconsider page 97 of Sputtek et al. (In: Clinical Applications in Cryobiology, CRC Press, 1991), where it is noted that the conditions employed to freeze red blood cells do not result in viable white blood cells (a copy was provided with the Amendment filed on August 27, 2001). Further, in Hubel (Transfusion Med. Rev., 11, 224 (1997)) (a copy was provided with the Amendment filed on August 27, 2001), it is disclosed that the membrane permeability parameters for a number of blood cell types including lymphocytes was found to be distinctive (see Table 1). In addition, Figure 3 in Hubel provides data showing that freshly isolated CD34⁺ cells and cultured, transduced CD34⁺ cells have different physical characteristics at different temperatures, including water permeability, cell volume and the osmotically inactive cell volume fraction (page 228).

Yet further evidence that different cell types have different properties in any particular cryopreservation medium is shown in Table 3 and 4 of Applicant's specification. Tables 3 and 4 show the differences in cell recovery for activated peripheral blood lymphocytes versus cultured peripheral blood lymphocytes and genetically altered peripheral blood lymphocytes versus normal peripheral blood lymphocytes in the same AG-containing cryopreservation medium and relative to DMSO-containing medium.

Because the concentration of AG useful in a cryopreservation medium is based on the biophysical properties of each cell type, and so varies with cell type, Dr. Hubel concluded in the

Declaration that the disclosure in WO 97/35272 does not enable a cryopreservation composition for freshly isolated lymphocytes, hematopoietic stem cells or lymphocytes which are modified *ex vivo* or a method to cryopreserve those cells.

Accordingly, WO 97/35472 does not anticipate or render obvious Applicant's invention. Therefore, the Examiner is respectfully requested to withdraw the § 102(a) and § 103(a) rejections of the claims.

Conclusion

Applicant respectfully submits that the claims are in condition for allowance and notification to that effect is earnestly requested. The Examiner is invited to telephone Applicant's attorney (612-373-6959) to facilitate prosecution of this application.

If necessary, please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

Respectfully submitted,

ALLISON HUBEL,

By her Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6959

Date

May 2, 2002

By

Janet E. Embretson
Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on this 2nd day of May, 2002.

Name

Dawn M. Poole

Signature

Dawn M. Poole